ReviewJournal of the Society for Cardiovascular Angiography & Interventions2026
Reduced-Dose vs Full-Dose Direct Oral Anticoagulants for Extended Anticoagulation Therapy in Patients With Venous Thromboembolism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Review in Journal of the Society for Cardiovascular Angiography & Interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extended anticoagulation therapy is often required in patients with venous thromboembolism (VTE), but the optimal dosing strategy remains unclear. This study aimed to evaluate the efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants in the extended treatment of VTE. Methods: We systematically searched PubMed, Embase, and Cochrane for randomized controlled trials (RCT) comparing reduced-dose versus full-dose direct oral anticoagulants for extended anticoagulation therapy in VTE. Primary outcomes included major bleeding, recurrent VTE, all-cause mortality, and clinically relevant nonmajor bleeding. Secondary outcomes included pulmonary embolism and upper limb deep vein thrombosis. Statistical analysis was performed using R 4.4.2. Quality assessment of included RCT was conducted using the Cochrane Risk of Bias 2 tool. Results: We included 8781 patients from 5 RCT with 50.1% (n = 4395) receiving reduced-dose anticoagulation; 21.7% (n = 1908) had active cancer, and 18.1% (n = 1585) had a history of previous deep vein thrombosis/pulmonary embolism. Major bleeding (1.2% vs 2.0%; risk ratio [RR], 0.62; 95% CI, 0.42-0.92; Conclusions: Reduced-dose anticoagulation demonstrates significantly lower bleeding risk compared to full-dose in VTE patients, with comparable efficacy in preventing recurrent VTE and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.